Literature DB >> 32202371

Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people.

Masatsugu Ohara1, Goki Suda1, Megumi Kimura1, Osamu Maehara2, Tomoe Shimazaki1, Taku Shigesawa1, Kazuharu Suzuki1, Akihisa Nakamura1, Naoki Kawagishi1, Masato Nakai1, Takuya Sho1, Mitsuteru Natsuizaka1, Kenichi Morikawa1, Koji Ogawa1, Tomoe Kobayashi3, Minoru Uebayashi4, Ryo Takagi5, Isao Yokota5, Tsuyoshi Shimamura6, Naoya Sakamoto1.   

Abstract

This study aimed to determine the optimal psoas muscle mass index (PMI) cut-off values for diagnosis of skeletal muscle mass loss.
METHODS: We evaluated PMI in two groups of normal controls: a medical check-up group and a liver donation candidate group. We analyzed two novel PMI cut-off values, one based on the mean - two standard deviations (2SD) and one based on the lower 5%. Skeletal muscle mass index (SMI) evaluations using computed tomography (sliceOmatic; TomoVision) and bioelectrical impedance analysis and PMI evaluation were undertaken simultaneously. We analyzed the correlation between our PMI cut-off values and the Japan Society of Hepatology-defined SMI cut-off values. The prevalence of skeletal muscle mass loss in patients with liver disease was assessed using the novel PMI cut-off values.
RESULTS: In 504 normal controls aged ≤50 years, the PMI cut-off values based on mean -2SD and the lower 5% were set at 3.30 cm2 /m2 for men and 1.69 cm2 /m2 for women and 3.74 cm2 /m2 for men and 2.29 cm2 /m2 for women, respectively. The PMI cut-off values based on the lower 5% alone showed that skeletal muscle mass loss increased with age. Furthermore, they correlated well with Japan Society of Hepatology-defined SMI (sliceOmatic) cut-off values and showed a significantly higher prevalence of skeletal muscle mass loss in patients with liver cirrhosis than those without liver cirrhosis.
CONCLUSIONS: We propose the following PMI cut-off values: 3.74 cm2 /m2 for male individuals and 2.29 cm2 /m2 for female individuals. These cut-off values can facilitate accurate diagnosis and management of sarcopenia in patients with chronic liver disease.
© 2020 The Japan Society of Hepatology.

Entities:  

Keywords:  liver disease; psoas muscle; sarcopenia; skeletal muscle

Year:  2020        PMID: 32202371     DOI: 10.1111/hepr.13499

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  7 in total

1.  Low preoperative psoas muscle mass index is a risk factor for distal cholangiocarcinoma recurrence after pancreatoduodenectomy: a retrospective analysis.

Authors:  Saori Umezawa; Shinjiro Kobayashi; Takehito Otsubo
Journal:  World J Surg Oncol       Date:  2022-06-02       Impact factor: 3.253

Review 2.  Radiologic Definition of Sarcopenia in Chronic Liver Disease.

Authors:  Chul-Min Lee; Bo Kyeong Kang; Mimi Kim
Journal:  Life (Basel)       Date:  2021-01-25

3.  Effects of In-Hospital Physical Therapy on Activities of Daily Living in Patients with Hepatocellular Carcinoma.

Authors:  Hayato Narao; Keisuke Hirota; Shunji Koya; Manabu Tomita; Yuta Manako; Satosi Ogawa; Naomi Nakao; Tsubasa Tsutsumi; Dan Nakano; Ryuki Hashida; Takumi Kawaguchi; Hiroo Matsuse; Hiroaki Nagamatu; Takuji Torimura
Journal:  Int J Environ Res Public Health       Date:  2020-12-06       Impact factor: 3.390

Review 4.  Definition of Sarcopenia in Chronic Liver Disease.

Authors:  Seong Wan Son; Do Seon Song; U Im Chang; Jin Mo Yang
Journal:  Life (Basel)       Date:  2021-04-16

5.  Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150.

Authors:  Takuya Sho; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Koji Ogawa; Akinori Kubo; Yoshimasa Tokuchi; Qingjie Fu; Zijian Yang; Megumi Kimura; Takashi Kitagataya; Osamu Maehara; Shunsuke Ohnishi; Akihisa Nakamura; Ren Yamada; Masatsugu Ohara; Naoki Kawagishi; Mitsuteru Natsuizaka; Masato Nakai; Kazuharu Suzuki; Takaaki Izumi; Takashi Meguro; Katsumi Terashita; Tomofumi Takagi; Jun Ito; Tomoe Kobayashi; Takuto Miyagishima; Naoya Sakamoto
Journal:  Cancers (Basel)       Date:  2022-08-15       Impact factor: 6.575

6.  Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.

Authors:  Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Satoshi Abiko; Kenji Kinoshita; Shuichi Miyamoto; Ryo Sugiura; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Taku Shigesawa; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
Journal:  PLoS One       Date:  2022-01-20       Impact factor: 3.240

7.  Diagnosing sarcopenia: Functional perspectives and a new algorithm from the ISarcoPRM.

Authors:  Murat Kara; Bayram Kaymak; Walter Frontera; Ayşe Merve Ata; Vincenzo Ricci; Timur Ekiz; Ke-Vin Chang; Der-Sheng Han; Xanthi Michail; Michael Quittan; Jae-Young Lim; Jonathan F Bean; Franco Franchignoni; Levent Özçakar
Journal:  J Rehabil Med       Date:  2021-06-21       Impact factor: 2.912

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.